|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Tanabe_Seiyaku
gptkb:Mitsubishi_Pharma_Corporation
|
|
gptkbp:basedOn
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:contributedTo
|
medical research
|
|
gptkbp:develops
|
biologics
small molecules
|
|
gptkbp:employs
|
over 7,000 people
|
|
gptkbp:engagesIn
|
clinical trials
|
|
gptkbp:focusesOn
|
therapeutics for autoimmune diseases
therapeutics for diabetes
therapeutics for neurological disorders
|
|
gptkbp:founded
|
2007
|
|
gptkbp:hasAwards
|
various industry awards
|
|
gptkbp:hasCollaborationsWith
|
research institutions
healthcare_organizations
|
|
gptkbp:hasImpactOn
|
diverse product portfolio
strong revenue growth
|
|
gptkbp:hasPartnershipsWith
|
biotech companies
various universities
|
|
gptkbp:hasProductLine
|
gptkb:Radicava
Vasopressin
Mizoribine
Seroquel
Sustol
|
|
gptkbp:hasResearchInterest
|
in_Europe
in_the_USA
in_Japan
|
|
gptkbp:hasSpecialty
|
programs
|
|
gptkbp:hasSubsidiary
|
gptkb:Mitsubishi_Tanabe_Pharma_Europe
gptkb:Mitsubishi_Tanabe_Pharma_Canada
gptkb:Mitsubishi_Tanabe_Pharma_America
|
|
gptkbp:hasTheme
|
numerous pharmaceutical patents
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mitsubishi Tanabe Pharma
|
|
gptkbp:isInvolvedIn
|
public health initiatives
community health programs
global health issues
|
|
gptkbp:isKnownFor
|
high-quality standards
innovative therapies
commitment to sustainability
|
|
gptkbp:isRecognizedBy
|
industry analysts
patients
healthcare_professionals
|
|
gptkbp:operatesIn
|
global markets
|
|
gptkbp:parentCompany
|
gptkb:Mitsubishi_Chemical_Holdings_Corporation
|
|
gptkbp:participatesIn
|
healthcare_initiatives
|
|
gptkbp:specializesIn
|
research and development
|
|
gptkbp:supports
|
patient advocacy groups
|